Page 16 - Génome Québec - 2017-2018 Annual report

FINANCIAL STATEMENT OF FINANCIAL POSITION

ACTIVITY REPORT MARCH 31 2018, WITH COMPARATIVE
INFORMATION FOR 2017

Génome Québec receives most of its financial year. Strategic development expenses totalled $222,157. After The Statement of Financial Position as at March 31, 2018 the full financial statements of Génome Québec. These full
support from the Québec government and certain adjustments, these expenses represent 3.6% of total and 2017, and the Statement of Operations for the years financial statements, available in French only, were audited by
Genome Canada for the funding of research investments for the year. Investment and intellectual property ended March 31, 2018 and 2017 that follow are provided as KPMG LLP, Chartered Professional Accountants, and reported
on June 19, 2018.
revenues reached $657,695, for a return of 1.24%.
illustrative summaries only and are not intended to replace
projects and the operation of its technology
centres. The excess of revenue over expenses totalling $1,149,322
is the combined effect of the surplus of $805,983 generated
As of March 31, 2018, our research portfolio includes by the technology centres, the investment and intellectual ASSETS
59 research projects, while three technology centres are cur- property revenues of $657,695, minus activities carried out 2018 ($) 2017 ($)
rently in operation. Génome Québec invested $53.5 million without government funding, that is strategic development of
during the 2017-2018 fiscal year. This amount, combined with $222,157 and support to researchers of $92,199. Unrestricted
the $29.4 million invested by other partners, brings our overall net assets were up $274,379, reaching a total of $2,423,643 on Current Assets
injection of funds to $82.9 million, a decrease of 6.3% over March 31, 2018. Net assets dedicated to activities increased Cash and cash equivalents 4,504,807 41,431,851
last year. by $587,801 during the fiscal year and represent a net balance
of $662,388. The technology investment and contingency Short-term investments 20,446,553 12,347,946
Business volume generated by research projects during this funds net assets totals $1,577,133.
fiscal year amounted to $62 million. The most important activi- Contributions receivable 3,161,000 -
ties are from the Genomics and Personalized Health compe- Finally, Génome Québec has respected the terms and condi-
tition and the Fonds de partenariat pour un Québec innovant tions in compliance with the contractual agreements it has Accounts receivable and work in progress 2,767,582 4,365,069
et en santé. This year, new projects issued from the Genomic signed with its major financial partners. Advances to genomics research projects - 7,606,302
Applications Partnership Program and the Societal Implica-
tions of Genomics Research competition were launched. The Inventories 1,430,704 2,126,461
budget for projects underway totals $352 million, $84 million
of which is still to be carried out. Prepaid expenses 163,212 126,256
$32,473,858 $68,003,885
For the year ended on March 31, 2018, sales arising from the
technology centres totalled $13.9 million, down 16.1% com-
pared to last year. However, the technology centres posted an
excess of revenues over expenses of $805,983 compared to Long-term investments 28,099,774 -
$685,373 from the previous fiscal year.

General and administrative expenses, business development Daniel Coderre Claude Lamarre Capital assets
and communications and committee expenses amounted to President and CEO Vice President, Finance 251,769 393,582
$2.7 million, a decrease of $190,735 compared to last fiscal Génome Québec Génome Québec

$60,825,401 $68,397,467

016 2017-2018 ANNUAL REPORT